الفهرس 
AcknowledgmentOnly 14 pages are availabe for public view
 |  | from | 99 |  |  |
| | | from | 99 | | |
Abstract
ConclusionConclusion
In type 2 diabetes mellitus MPV is in¬creased and it is indicative of worsening glycemic control. Increased platelet size may be one factor in the increased risk of atherosclerosis as¬sociated with diabetes mellitus and associated vas¬cular complications. Hence, MPV would be a useful prognostic marker of macro-micro vascular complications in diabetes. There are relationships among MPV and other cardiovascular risk factors as age, gender, HTN and smoking as described above. Early initiation of insulin treatment in confirmed cases of Type 2 diabetics not only helps in controlling blood glucose level but also helps in keeping MPV low and thereby preventing possibil¬ity of impending vascular events.
Summary
Platelet hyperactivity in DM may be one factor in the severe and profound vasculopathies that are so often associated with this disorder. There are studies that have shown increased platelet aggregation in diabetes mellitus, and this may have a role in its vascular complications. Activated platelets respond to activated leukocytes and endothelial cells via adhesion molecules linking inflammation and thrombosis.
Platelet volume is a marker of platelet function and activation. It is measured as mean platelet volume (MPV) by clinical hematology analyzers.
In this study, the aim of the work is
(1) To compare the MPV in diabetics with that in age- and sex-matched non diabetic healthy controls.
(2) To see whether there is a difference in MPV between diabetic patients with and without macro and micro vascular complications.
(3) To determine the correlation between MPV and glycemic control.
Our study included 100 consecutive Type 2 diabetic patients (49 females and 51 males); mean age was 49 ± 14 years. Diabetic patients were evaluated clinically and laboratory as accepted in protocol of the study. There were 42 patients on insulin versus 58 patients on OHG. There were 46 patients hypertensive versus 54 patients not hypertensive. There were 28 patients smokers versus 72 patients not smokers. The age and sex-matched control group consisted of 50 healthy non diabetic subjects. None of the diabetic patients and controls had any thrombotic and hematological diseases. None of them had received anticoagulant medications.
Total population (diabetics & non-diabetics) included in the study almost in the same range of age and number of males almost equal to number of females.
Both groups (controlled & uncontrolled DM) have almost the same range of duration of DM and almost equal number of patients on insulin therapy versus OHG therapy in both groups, and no significant difference among diabetics and non-diabetics as regard HTN and smoking.
The study showed the following
Significant increase in MPV with diabetes mellitus.
Significant increase in MPV with poor glycemic control.
Significant increase in vascular complications of DM with higher MPV.
Variable degrees of relationship among MPV and different cardiovascular risk factors as age, gender, smoking, hypertension.
Significant relationship between MPV and type of treatment of DM (insulin versus OHG), MPV higher with OHG therapy versus insulin therapy as mean that insulin has protective role against chronic vascular complications of DM.
So, in type 2 diabetes mellitus MPV is in¬creased and it is indicative of worsening glycemic control. Increased platelet size may be one factor in the increased risk of atherosclerosis as¬sociated with diabetes mellitus and associated vas¬cular complications. Hence, MPV would be a useful prognostic marker of macro-micro vascular complications in diabetes. There are relationships among MPV and other cardiovascular risk factors as age, gender, HTN and smoking as described above. Early initiation of insulin treatment in confirmed cases of Type 2 diabetics not only helps in controlling blood glucose level but also helps in keeping MPV low and thereby preventing possibil¬ity of impending vascular events.